Sales of Novo Nordisk's blockbuster Wegovy weight loss drug surged in the second quarter, the company said in its latest ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit ...

Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a ...

Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...